0001078782-12-002656.txt : 20121016 0001078782-12-002656.hdr.sgml : 20121016 20121015173638 ACCESSION NUMBER: 0001078782-12-002656 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20120917 ITEM INFORMATION: Other Events FILED AS OF DATE: 20121016 DATE AS OF CHANGE: 20121015 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PHARMA INVESTING NEWS, INC. CENTRAL INDEX KEY: 0001520047 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMPUTER PROCESSING & DATA PREPARATION [7374] IRS NUMBER: 320337695 STATE OF INCORPORATION: NV FISCAL YEAR END: 0228 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-54738 FILM NUMBER: 121144583 BUSINESS ADDRESS: STREET 1: 1810 EAST SAHARA AVE STREET 2: SUITE 1571 CITY: LAS VEGAS STATE: NV ZIP: 89104 BUSINESS PHONE: 702-664-6555 MAIL ADDRESS: STREET 1: 1810 EAST SAHARA AVE STREET 2: SUITE 1571 CITY: LAS VEGAS STATE: NV ZIP: 89104 8-K 1 f8k081512_8k.htm FORM 8-K Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549


FORM 8-K


CURRENT REPORT


Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 17, 2012


Pharma Investing News, Inc.

 (Exact name of registrant as specified in its charter)


Nevada

(State or other jurisdiction of incorporation)


000-54738

(Commission File Number)


32-0337695

 (IRS Employer Identification No.)


1810 East Sahara Ave, Suite 1571

Las Vegas, Nevada, 89104

 (Address of principal executive offices)(Zip Code)


(702) 664-6555

(Registrant’s telephone number, including area code)


 (Former name or former address, if changed since last report.)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


      .

 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


      .

 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


      .

 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


      .

 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))




Item 8.01 Other Events.


On September 17, 2012, Carrillo Huettel, LLC, resigned as legal counsel to Pharma Investing News, Inc. (the “Company”).  Such resignation was not the result of any disagreement with the Company.  The Company’s new legal counsel is the Law Offices of Thomas E. Puzzo, PLLC.


SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Pharma Investing News, Inc.

(Registrant)



Date:  October 15, 2012

       By:  /s/    Robert Lawrence           

Name:  Robert Lawrence

Title: President and CEO






2